1. Home
  2. JQC vs ARVN Comparison

JQC vs ARVN Comparison

Compare JQC & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

JQC

Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

N/A

Current Price

$4.76

Market Cap

753.9M

Sector

Finance

ML Signal

N/A

Logo Arvinas Inc.

ARVN

Arvinas Inc.

N/A

Current Price

$13.35

Market Cap

781.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
JQC
ARVN
Founded
2003
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
753.9M
781.0M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
JQC
ARVN
Price
$4.76
$13.35
Analyst Decision
Buy
Analyst Count
0
21
Target Price
N/A
$15.71
AVG Volume (30 Days)
823.8K
749.6K
Earning Date
01-01-0001
05-27-2026
Dividend Yield
11.13%
N/A
EPS Growth
N/A
58.84
EPS
N/A
N/A
Revenue
N/A
$262,600,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.60
$5.90
52 Week High
$5.58
$14.22

Technical Indicators

Market Signals
Indicator
JQC
ARVN
Relative Strength Index (RSI) 26.33 55.13
Support Level N/A $11.07
Resistance Level $5.16 $13.97
Average True Range (ATR) 0.05 0.75
MACD -0.02 0.09
Stochastic Oscillator 8.62 78.86

Price Performance

Historical Comparison
JQC
ARVN

About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.

About ARVN Arvinas Inc.

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Share on Social Networks: